$CMRX
CHIMERIX INC Stock $cmrx

$cmrx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000111748023000018 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$26.00K	$283.0K
YoY Change	-94.09%	1786.67%
Cost Of Revenue	$0.00	$0.00
YoY Change		-100.0%
Gross Profit	$26.00K	$283.0K
YoY Change	-94.09%	-385.86%
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$4.448M	$5.679M
YoY Change	-23.84%	0.83%
% of Gross Profit	17107.69%	2006.71%
Research & Development	$16.93M	$18.82M
YoY Change	-6.21%	-1.14%
% of Gross Profit	65100.0%	6650.88%
Depreciation & Amortization	$23.00K	$22.00K
YoY Change	-4.17%	-8.33%
% of Gross Profit	88.46%	7.77%
Operating Expenses	$21.37M	$24.50M
YoY Change	-10.52%	-0.69%
Operating Profit	-$21.35M	-$24.22M
YoY Change	-8.95%	-2.23%
Interest Expense	$2.772M	$2.846M
YoY Change	-13300.0%	71050.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.58M	-$21.37M
YoY Change	-20.85%	-13.71%
Income Tax
% Of Pretax Income
Net Earnings	-$18.58M	-$21.37M
YoY Change	-20.85%	-13.71%
Net Earnings / Revenue	-71446.15%	-7551.94%
Basic Earnings Per Share	-$0.21	-$0.24
Diluted Earnings Per Share	-$0.21	-$0.24
COMMON SHARES
Basic Shares Outstanding	88.58M shares	88.27M shares
Diluted Shares Outstanding	88.58M shares	88.29M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$205.8M	$214.8M
YoY Change	380.84%	302.32%
Cash & Equivalents	$20.10M	$15.95M
Short-Term Investments	$185.7M	$198.8M
Other Short-Term Assets	$5.735M	$9.330M
YoY Change	48.85%	61.81%
Inventory
Prepaid Expenses
Receivables	$26.00K	$668.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$211.5M	$224.8M
YoY Change	316.62%	259.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.984M	$267.0K
YoY Change	867.8%	16.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$27.26M	$31.32M
YoY Change
Other Assets	$326.0K	$346.0K
YoY Change	-18.3%	-21.18%
Total Long-Term Assets	$29.57M	$33.78M
YoY Change	958.65%	1039.01%
TOTAL ASSETS
Total Short-Term Assets	$211.5M	$224.8M
Total Long-Term Assets	$29.57M	$33.78M
Total Assets	$241.1M	$258.5M
YoY Change	350.1%	294.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.823M	$2.847M
YoY Change	4.59%	-18.52%
Accrued Expenses	$13.52M	$13.58M
YoY Change	-18.97%	15.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.34M	$16.43M
YoY Change	-34.08%	8.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.632M	$1.791M
YoY Change	-30.96%	-28.53%
Total Long-Term Liabilities	$1.632M	$1.791M
YoY Change	-30.96%	-28.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.34M	$16.43M
Total Long-Term Liabilities	$1.632M	$1.791M
Total Liabilities	$16.97M	$18.22M
YoY Change	-33.79%	2.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$753.4M	-$734.8M
YoY Change	-19.32%	-19.28%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$224.1M	$240.3M
YoY Change
Total Liabilities & Shareholders Equity	$241.1M	$258.5M
YoY Change	350.1%	294.61%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$18.58M	-$21.37M
YoY Change	-20.85%	-13.71%
Depreciation, Depletion And Amortization	$23.00K	$22.00K
YoY Change	-4.17%	-8.33%
Cash From Operating Activities	-$14.34M	-$22.23M
YoY Change	35.81%	-5.21%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$62.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$18.53M	$12.20M
YoY Change	176.61%	-77.19%
Cash From Investing Activities	$18.52M	$12.14M
YoY Change	176.43%	-77.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-31.00K	$199.0K
YoY Change	181.82%	-101.48%
NET CHANGE
Cash From Operating Activities	-14.34M	-$22.23M
Cash From Investing Activities	18.52M	$12.14M
Cash From Financing Activities	-31.00K	$199.0K
Net Change In Cash	4.148M	-$9.891M
YoY Change	-207.16%	-159.73%
FREE CASH FLOW
Cash From Operating Activities	-$14.34M	-$22.23M
Capital Expenditures	$12.00K	$62.00K
Free Cash Flow	-$14.35M	-$22.29M
YoY Change	35.93%	-4.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001117480
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35867
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CHIMERIX, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0903395
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2505 Meridian Parkway
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Durham
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27713
CY2023Q1	dei	City Area Code CityAreaCode	919
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	806-1074
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CMRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88583567	shares
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15951000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25842000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	198801000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	191492000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	668000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1040000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9330000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9764000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	224750000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	228138000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	31322000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	48626000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	227000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1848000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1964000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	346000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	386000	usd
CY2023Q1	us-gaap	Assets Assets	258533000	usd
CY2022Q4	us-gaap	Assets Assets	279341000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2847000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3034000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13584000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17381000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16431000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20415000	usd
CY2023Q1	cmrx	Loan Fees Liability Non Current LoanFeesLiabilityNonCurrent	125000	usd
CY2022Q4	cmrx	Loan Fees Liability Non Current LoanFeesLiabilityNonCurrent	250000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1666000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1819000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	18222000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	22484000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88583567	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88583567	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88054127	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88054127	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	89000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	88000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	975254000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	970535000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-231000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-337000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-734801000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-713429000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	240311000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	256857000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	258533000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	279341000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	283000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	114000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	283000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	-99000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	18822000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19040000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5679000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5632000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	24501000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	24672000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24218000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24771000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2846000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21372000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24767000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	106000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-52000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21266000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24819000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88294624	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88294624	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87088804	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87088804	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	256857000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4363000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	357000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	106000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21372000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21266000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	240311000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	68252000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3708000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	102000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	555000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-52000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24767000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24819000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	47798000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-21372000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24767000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	22000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	24000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	66000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	33000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2096000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-53000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4363000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3708000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1000	usd
CY2023Q1	cmrx	Operating Lease Right Of Use Asset Amortization Expense And Straight Line Rent OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent	-20000	usd
CY2022Q1	cmrx	Operating Lease Right Of Use Asset Amortization Expense And Straight Line Rent OperatingLeaseRightOfUseAssetAmortizationExpenseAndStraightLineRent	63000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-371000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	646000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-441000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1002000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-912000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22225000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23447000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5258000	usd
CY2023Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	6803000	usd
CY2022Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7699000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	19000000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	51026000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12135000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	53467000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	102000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	356000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	556000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	157000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	118000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-14000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	199000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13460000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9891000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16560000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25842000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15397000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15951000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31957000	usd
CY2022Q3	cmrx	Employee Retention Credit EmployeeRetentionCredit	2000000	usd
CY2023Q1	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	27000	usd
CY2023Q1	cmrx	Accrued Development Liabilities AccruedDevelopmentLiabilities	7936000	usd
CY2022Q4	cmrx	Accrued Development Liabilities AccruedDevelopmentLiabilities	6691000	usd
CY2023Q1	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	3348000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	6438000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2300000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4252000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13584000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17381000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	47000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In addition to estimates discussed in other sections of this Quarterly Report on Form 10-Q, the most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	230354000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	64000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	295000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	230123000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	240455000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	384000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	240118000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	173832000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	295000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	173832000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	295000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	51	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	51	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	179254000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	384000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	179254000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	384000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	55	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	55	security
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	198801000	usd
CY2023Q1	cmrx	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwo	31322000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	230123000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M2D
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0789
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	306000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1848000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	590000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1666000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2256000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	555000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	759000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	781000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	467000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2562000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2256000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	736000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	759000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	781000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	467000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2743000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	351000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2392000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	221000	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	134000	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4363000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3708000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	400000	usd
CY2023Q1	us-gaap	Severance Costs1 SeveranceCosts1	600000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	cmrx	Contract Close Out Costs ContractCloseOutCosts	799000	usd
CY2022Q2	cmrx	Contract Close Out Liability ContractCloseOutLiability	4539000	usd
	cmrx	Contract Close Out Liability Adjustments ContractCloseOutLiabilityAdjustments	-746000	usd
	cmrx	Contract Close Out Liability Payments ContractCloseOutLiabilityPayments	2482000	usd
CY2022Q4	cmrx	Contract Close Out Liability ContractCloseOutLiability	1311000	usd
CY2022Q4	cmrx	Contract Close Out Liability ContractCloseOutLiability	1311000	usd
CY2023Q1	cmrx	Contract Close Out Liability Adjustments ContractCloseOutLiabilityAdjustments	10000	usd
CY2023Q1	cmrx	Contract Close Out Liability Payments ContractCloseOutLiabilityPayments	250000	usd
CY2023Q1	cmrx	Contract Close Out Liability ContractCloseOutLiability	1071000	usd
CY2023Q1	cmrx	Contract Close Out Liability Adjustments ContractCloseOutLiabilityAdjustments	10000	usd
CY2022Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	20	employee
CY2022Q4	us-gaap	Severance Costs1 SeveranceCosts1	1900000	usd
CY2022Q4	cmrx	Anticipated Severance Cost AnticipatedSeveranceCost	1000000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	400000	usd
CY2022Q4	us-gaap	Severance Costs1 SeveranceCosts1	1854000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	1442000	usd
CY2023Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-73000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	641000	usd
CY2023Q1	us-gaap	Restructuring Reserve RestructuringReserve	728000	usd

Files In Submission

Name	View Source	Status
0001117480-23-000018-index-headers.html	Edgar Link	pending
0001117480-23-000018-index.html	Edgar Link	pending
0001117480-23-000018.txt	Edgar Link	pending
0001117480-23-000018-xbrl.zip	Edgar Link	pending
a20230331cmrxex-311.htm	Edgar Link	pending
a20230331cmrxex-312.htm	Edgar Link	pending
a20230331cmrxex-321.htm	Edgar Link	pending
a20230331cmrxex-322.htm	Edgar Link	pending
cmrx-20230331.htm	Edgar Link	pending
cmrx-20230331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
cmrx-20230331_cal.xml	Edgar Link	unprocessable
cmrx-20230331_lab.xml	Edgar Link	unprocessable
cmrx-20230331_def.xml	Edgar Link	unprocessable
cmrx-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cmrx-20230331_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMRX
CHIMERIX INC Stock $cmrx

2023 Q2 Form 10-Q Financial Statement

#000111748023000018 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMRX CHIMERIX INC Stock $cmrx

2023 Q2 Form 10-Q Financial Statement

#000111748023000018 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMRX
CHIMERIX INC Stock $cmrx